Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819

Clinical Cancer Research

Volumn 18, Issue 15, 2012, Pages 4004-4012

  Redman, Mary W ^a   Crowley, John J ^a   Herbst, Roy S ^b   Hirsch, Fred R ^c   Gandara, David R ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PHARMACOLOGICAL BIOMARKER;

ADVANCED CANCER; ALL COMERS DESIGN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISCRETE HYPOTHESIS DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG USE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE HYPOTHESIS DESIGN; NULL HYPOTHESIS; OVERALL POPULATION FOCUSED DESIGN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; REVIEW; SIMULATION; STRATEGY DESIGN; STUDY DESIGN; TARGETED DESIGN; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84864489915     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0167     Document Type: Review

References (22)

1. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol 2010;28:4747-54.
2. Gandara DR, Kim ES, Herbst RS. S0536: Carboplatin, paclitaxel, cetuximab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer: a SWOG phase II study. J Clin Oncol 27:15s, 2009 (suppl: abst 8015).
3. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
4. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-7.
5. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7.
6. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42. (Pubitemid 46631407)
7. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807. (Pubitemid 46606235)
8. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res 2008;14:4358-67.
9. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
10. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8. (Pubitemid 41611633)
11. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al.SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
12. Kim ES, Hirsh V, Mok TS, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
13. Wakelee H, Kernstine K, Vokes E, Schiller J, Baas P, Saijo N, et al. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2008;9:346-51.
14. Spiessens B, Debois M. Adjusted significance levels for subgroup analyses in clinical trials. Contemp Clin Trials 2010;31:647-56.
15. Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, et al.Southwest Oncology Group Trial S0003. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-smallcell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005;23:9097-104.
16. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
17. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102:152-60.
18. O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12:795-805.
19. Pirker R, Paz Ares L, Eberhardt W, Krzakowski M, St€orkel S, Heeger S, et al. High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy. In: Proceedings of the 14th World Conference on Lung Cancer; 2011 July 3-7; Amsterdam: IASLC.
20. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918-27.
21. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7. (Pubitemid 46211382)
22. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-63. (Pubitemid 39383023)